Skip to main content
. Author manuscript; available in PMC: 2022 Jul 29.
Published in final edited form as: Clin Pharmacokinet. 2021 Feb 2;60(6):795–809. doi: 10.1007/s40262-020-00977-w

Figure 5. Sensitivity analysis of dosing of emtricitabine, dolutegravir and raltegravir in newborns.

Figure 5.

A: Emtricitabine plasma concentration in newborns with differing dosing; maternal dose of 400 mg single dose. Empty circles represent observed data were taken from Hirt et al [17] and black circles represent median observed data. B: dolutegravir plasma concentration in newborns with differing dosing; maternal dose of 50 mg once a day. Empty circles represent observed data were taken from IMPAACT P1026 [10] and black circles represent median observed data. C: raltegravir plasma concentration in newborns with differing dosing; maternal dose of 400 mg twice a day. Empty circles represent observed data were taken from Clarke et al. [16] and black circles represent median observed data.